An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback